Hepatitis Vaccines: Safety, Efficacy and Global Impact

Dear Colleagues,

Hepatitis vaccines are among the most significant achievements in public health, providing highly effective protection against viral hepatitis, a leading global cause of liver disease and death. Hepatitis A and B vaccines, with immunogenicity rates exceeding 95%, offer long-lasting protection and have been instrumental in reducing hepatitis-related infections and deaths, particularly in regions with well-established vaccination programs. However, despite these successes, challenges remain in ensuring equitable vaccine access, especially in low-resource settings where the burden of hepatitis is highest. While a hepatitis E vaccine is available in certain regions and research into vaccines for hepatitis C and D continues, there is still a critical need for innovation and expanded global reach in prevention strategies. Addressing these gaps through education, improved access, and integration into public health frameworks is crucial to achieving the World Health Organization’s goal of eliminating viral hepatitis as a public health threat by 2030.

In this Special Issue, we aim to address key questions related to viral hepatitis, including its prevention through vaccination, the safety and efficacy of current vaccines, and the broader global impact of these interventions. We invite the submission of original research and review articles that explore any aspect of viral hepatitis, the role of vaccines, and the innovations and challenges that will shape the future of hepatitis prevention worldwide.

Dr. Muhammad Atif Zahoor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.